Nikodimopoulou M, Liakos S
1 Propedeutic Medical Department, AHEPA Hospital, Aristotles University of Thessaloniki,Greece.
Hippokratia. 2011 Jan;15(Suppl 1):33-8.
Secondary hyperparathyroidism (SHPT) is a common disorder in patients with chronic kidney disease (CKD) and is characterized by excessive serum parathyroid hormone (PTH) levels, parathyroid hyperplasia and an imbalance in calcium and phosphorus metabolism. Secondary hyperparathyroidism develops early in the course of CKD and becomes more prominent as kidney function declines.PTH is a major uremic toxin and may be responsible for long-term consequences that include renal osteodystrophy, severe vascular calcifications, alterations in cardiovascular structure and function, immune dysfunction, and anemia. These adverse effects may contribute to an increased risk of cardiovascular morbidity and mortality among end-stage renal failure patients.
继发性甲状旁腺功能亢进（SHPT）是慢性肾脏病（CKD）患者的常见病症，其特征为血清甲状旁腺激素（PTH）水平过高、甲状旁腺增生以及钙磷代谢失衡。继发性甲状旁腺功能亢进在CKD病程早期就会出现，并随着肾功能下降而愈发显著。PTH是一种主要的尿毒症毒素，可能导致包括肾性骨营养不良、严重血管钙化、心血管结构和功能改变、免疫功能障碍及贫血等长期后果。这些不良反应可能会增加终末期肾衰竭患者心血管发病和死亡的风险。
